{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64.2","upperLimit":"85.0","value":"73.9"},{"groupId":"OG001","lowerLimit":"70.1","upperLimit":"99.7","value":"83.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"description":"The Kaplan-Meier method was used to estimate overall survival","dispersionType":"95% Confidence Interval","groups":[{"description":"Clinical impact of Morfeus software usage on patients undergoing percutaneous thermal ablation of liver tumors","id":"OG000","title":"Experimental"},{"description":"Morfeus software was not used during percutaneous ablation of hepatic mets","id":"OG001","title":"Control"}],"paramType":"NUMBER","populationDescription":"The 2-year secondary endpoints were evaluated for the randomized group","reportingStatus":"POSTED","timeFrame":"Overall survival was measured from the date of ablation to the date of death from any cause. Patients still alive were censored at the date of last clinic visit, with follow-up up to 24 months after ablation.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}